SLC5A2 and type 2 diabetes mellitus: To confirm the protective effects of SGLT2 inhibitors on the kidneys, the present study investigated the renoprotective effects of the highly selective SGLT2 inhibitor tofogliflozin using KK‐Ay mice as the model for type 2 diabetes.